Abstract #0245

Axon Loss as an Outcome Measure for Assessing Therapeutic Efficacy

Tsen-Hsuan Lin¹, Mitchell Hallman^1,2, Mattew F. Cusick³, Jane E. Libbey³, Peng Sun¹, Yong Wang^1,4,5,6, Robert S. Fujinami³, and Sheng-Kwei Song^1,5,6

¹Radiology, Washington University School of Medicine, St. Louis, MO, United States, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, ³Pathology, University of Utah School of Medicine, Salt Lake City, UT, United States, ⁴Obstertic and Gynecology, Washington University School of Medicine, St. Louis, MO, United States, ⁵The Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, United States, ⁶Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States

Diffusion basis spectrum imaging (DBSI) has successfully distinguished co-existing pathologies in CNS, such as MS. The utility of DBSI derived “axon volume” has not been explored previously. In this study, we demonstrated the use of axon loss, reflecting irreversible tissue damage, as an outcome measure for assessing therapeutic efficacy in a mouse model of multiple sclerosis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here